Antioxidant Therapeutics, Antibodies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
12
NCT03214666
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jan 1, 2020
Completion: Sep 29, 2021
Loading map...